Neurology • Bipolar

BXCL501—Agitation Takes Its Toll

BioXcel Therapeutics, Inc. is a clinical stage biopharmaceutical company focused on drug development that utilizes artificial intelligence to identify improved therapies in neuroscience and immuno-oncology.

BioXcel's most advanced product candidate is BXCL501, an investigational, muco-adhesive, orally-dissolving, sublingual thin film formulation of dexmedetomidine in development for the acute treatment of agitation resulting from neuropsychiatric disorders. The first two indications target agitation in patients with schizophrenia and bipolar 1 and 2 disorders.

Our unbranded campaign “Agitation Takes Its Toll” proposes to reset the balance for those who experience agitation associated with bipolar disorder ​and schizophrenia. Breaking through the resignation associated with the current treatment experience, BXCL501 is a transformative alternative that preserves humanity ​for a brave group of people who need it the most.

Work
Campaign
Social
Website
Tactics